Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

Original languageEnglish (US)
Pages (from-to)1551-1558
Number of pages8
JournalBlood
Volume127
Issue number12
DOIs
StatePublished - Mar 24 2016

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Luskin, M. R., Lee, J. W., Fernandez, H. F., Abdel-Wahab, O., Bennett, J. M., Ketterling, R. P., Lazarus, H. M., Levine, R. L., Litzow, M. R., Paietta, E. M., Patel, J. P., Racevskis, J., Rowe, J. M., Tallman, M. S., Sun, Z., & Luger, S. M. (2016). Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 127(12), 1551-1558. https://doi.org/10.1182/blood-2015-07-657403